Related Articles
Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice
Ezetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice
Establishment of a novel non‑alcoholic fatty liver disease model using cholesterol‑fed rabbits with reference to the potential role of endoplasmic reticulum stress
Sodium sulphate ameliorates hypercholesterolemia via the upregulation of <em>Cyp7a1</em> in hepatocytes and alleviates hepatic insulin resistance via the downregulation of <em>Trib3</em> in mice with high cholesterol diets
Alogliptin alleviates hepatic steatosis in a mouse model of nonalcoholic fatty liver disease by promoting CPT1a expression via Thr172 phosphorylation of AMPKα in the liver